Skip to main content
Pharming Group N.V. logo

Pharming Group N.V. — Investor Relations & Filings

Ticker · PHARM ISIN · NL0010391025 LEI · 724500DCJ9MPG74JEH91 AS Manufacturing
Open in API
Filings indexed 797 across all filing types
Latest filing 2023-12-15 Regulatory Filings
Country NL Netherlands
Listing AS PHARM

About Pharming Group N.V.

https://www.pharming.com/

Pharming Group N.V. is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company develops and commercializes an innovative portfolio of medicines to serve patients with unmet medical needs. Its portfolio includes protein replacement therapies, precision medicines, small molecules, and biologics.

Recent filings

Filing Released Lang Actions
6-K
Regulatory Filings
2023-12-15 English
Pharming Group announces development plans for leniolisib for additional primary immunodeficiencies (PIDs)
Regulatory Filings Classification · 95% confidence The document is a press release dated December 13, 2023, announcing Pharming Group N.V.'s plans to expand the development of leniolisib for additional Primary Immunodeficiencies (PIDs). It details upcoming clinical trial phases (Phase 2 study starting Q2 2024), provides scientific background on the drug and the diseases, includes quotes from management and external experts, and concludes with standard forward-looking statements and contact information. This format is characteristic of an initial announcement of significant corporate or clinical progress, which aligns best with the 'Earnings Release' (ER) category if it were financial results, but since it is a clinical/pipeline update announcement, it is most accurately classified as a general 'Regulatory Filing' (RNS) or potentially an 'Investor Presentation' (IP) if it were structured as slides. Given the structure as a formal press release announcing pipeline news and clinical plans, and lacking the specific structure of a formal Earnings Release (ER) which focuses on past period financial results, the most appropriate general category for a significant, non-standard announcement is RNS, as it is a regulatory disclosure of material information. However, since the content is a detailed announcement of clinical development plans and scientific rationale, it strongly resembles an Investor Presentation (IP) in content depth, but it is delivered as a press release. Given the options, and recognizing this is a material corporate update that isn't a standard financial report (10-K, IR, ER), RNS serves as the best fit for a general regulatory disclosure of this nature, although ER is often used for pipeline updates if they are tied to a reporting period. Since it is not explicitly an earnings release, RNS is the fallback for significant, non-categorized announcements.
2023-12-13 Dutch
Pharming Group announces development plans for leniolisib for additional primary immunodeficiencies (PIDs)
Regulatory Filings Classification · 99% confidence The document is a press release dated December 13, 2023, announcing Pharming Group N.V.'s plans to develop leniolisib for additional primary immunodeficiencies (PIDs) and the initiation of a Phase 2 clinical trial in Q2 2024. This type of announcement, detailing clinical development plans, regulatory feedback (FDA), and future trial timelines, is characteristic of a corporate update intended for investors and the public. It is not a full Annual Report (10-K), a formal Audit Report (AR), a transcript (CT), or a specific financial filing like a dividend notice (DIV) or insider trade report (DIRS). Since it is a general corporate announcement regarding pipeline development and clinical strategy, it fits best under the general 'Regulatory Filings' (RNS) category as a broad corporate disclosure, although it could also be considered an Investor Presentation (IP) if it were structured as slides. Given the format is a press release announcing strategic development plans, RNS serves as the most appropriate general disclosure category when a more specific category like 'IP' (Investor Presentation) or 'ER' (Earnings Release) is not explicitly warranted by the content structure (it's not a summary of past earnings). However, because it is a detailed announcement about clinical strategy and pipeline expansion, it strongly resembles an Investor Presentation or a specific corporate update that often accompanies investor relations activities. Given the options, and since it is a formal announcement of strategic business/clinical progress rather than just a miscellaneous regulatory filing, 'Investor Presentation' (IP) is a strong candidate if the content is meant for investor consumption, but 'Regulatory Filings' (RNS) is the safest fallback for non-standard press releases. Since it is a detailed announcement of future clinical plans and scientific rationale, it functions very similarly to an Investor Presentation, but without the slide deck format. I will classify it as a general Regulatory Filing (RNS) as it is a press release disclosing material, non-earnings-related corporate information.
2023-12-13 English
Pharming announces first patient dosed in pediatric clinical trial for children aged 1 to 6 years for leniolisib
Regulatory Filings Classification · 95% confidence The document is a press release from Pharming Group N.V. announcing that the first patient has been treated in a Phase III clinical trial for a pediatric formulation of leniolisib for APDS. It details the study design, includes quotes from a physician and the CMO, provides background on APDS and leniolisib, and concludes with standard forward-looking statements and contact information. This type of announcement, detailing the initiation or progress of clinical trials and providing key scientific/medical updates, is characteristic of an Earnings Release (ER) if it were tied to financial results, or more generally, a press release announcing significant operational/clinical milestones. Since it is not a full financial report (10-K, IR), a transcript (CT), or a formal regulatory filing like a proxy (DEF 14A), and it focuses on a specific clinical development milestone, it best fits the 'Earnings Release' category if we interpret ER broadly as a primary periodic corporate update, or 'Regulatory Filings' (RNS) as a general announcement. However, given the content is a direct announcement of a clinical trial milestone (first patient dosed) and includes medical context, it is a significant corporate update. In many databases, such detailed clinical progress announcements, especially when issued outside of a formal quarterly earnings report structure, are often categorized as general Regulatory Filings (RNS) or sometimes grouped with Earnings Releases (ER) if they contain forward-looking statements about future data. Since it is not explicitly an 'Earnings Release' summarizing financial performance, and it is a formal announcement of a corporate event (clinical trial start), RNS (Regulatory Filings) is the most appropriate fallback for a non-standard, yet important, corporate communication. Given the context of a bio-pharma company announcing a clinical trial step, it is a material event disclosure.
2023-11-21 English
Pharming announces first patient dosed in pediatric clinical trial for children aged 1 to 6 years for leniolisib
Regulatory Filings Classification · 95% confidence The document is a press release titled "Pharming announces first patient dosed in pediatric clinical trial for children aged 1 to 6 years for leniolisib." It details the initiation of a Phase III clinical trial, includes quotes from physicians and the CMO, provides background on the disease (APDS) and the drug (leniolisib), and concludes with standard corporate boilerplate and contact information. This format is characteristic of an announcement regarding clinical trial progress or a significant operational update, which is often released via a press release. Since it is not a full financial report (10-K, IR), a formal earnings release (ER), or a transcript (CT), and it relates to ongoing development and regulatory progress, it best fits the general category for corporate announcements that aren't strictly financial results or governance matters. Given the options, this type of announcement, which is essentially a regulatory/operational update, falls under the broad 'Regulatory Filings' (RNS) category, as it is a public disclosure of a material event, although it is not a specific SEC form. It is not an Earnings Release (ER) as it focuses on clinical trial initiation, not financial results.
2023-11-21 English
6-K
Regulatory Filings
2023-11-13 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.